|2.||Migraine Disorders (Migraine)
|5.||Alzheimer Disease (Alzheimer's Disease)
|1.||Dichgans, Martin: 38 articles (08/2015 - 01/2002)|
|2.||Chabriat, Hugues: 28 articles (08/2015 - 12/2002)|
|3.||Jouvent, Eric: 19 articles (01/2015 - 08/2008)|
|4.||Duering, Marco: 17 articles (06/2015 - 06/2009)|
|5.||Dotti, Maria Teresa: 17 articles (10/2014 - 04/2004)|
|6.||Federico, Antonio: 17 articles (10/2014 - 04/2004)|
|7.||Kalimo, Hannu: 15 articles (09/2014 - 05/2004)|
|8.||Opherk, Christian: 14 articles (03/2015 - 07/2004)|
|9.||Joutel, Anne: 13 articles (02/2015 - 02/2004)|
|10.||Viitanen, Matti: 13 articles (09/2014 - 05/2004)|
|1.||glucuronyl glucosamine glycan sulfate (Vessel)IBA
03/01/2011 - "Postmortem high-resolution MRI may help to detect intracortical infarcts in CADASIL and possibly in other small vessel diseases of the brain."
01/01/2014 - "ADC histograms from routine DWI for longitudinal studies in cerebral small vessel disease: a field study in CADASIL."
01/01/2014 - "Dilated perivascular spaces in small-vessel disease: a study in CADASIL."
10/01/2013 - "Depressive symptoms as a predictor of quality of life in cerebral small vessel disease, acting independently of disability; a study in both sporadic small vessel disease and CADASIL."
01/01/2012 - "NIHSS scores in ischemic small vessel disease: a study in CADASIL."
04/01/2013 - "The aim of this study was to evaluate the in vitro protective effects of Cere against oxidative stress-induced apoptosis in cells from CADASIL patients. "
04/01/2013 - "This result showed a protective effect of Cere against oxidative stress-induced apoptosis only in 30 % of the CADASIL patients, suggesting that the Notch3 gene probably does not influence the anti-apoptotic properties of Cere in vitro."
04/01/2013 - "Administration of Cere to PBLs from CADASIL patients cultured under standard conditions had no effect on the percentage of apoptotic cells. "
|3.||Acetazolamide (Diamox)FDA LinkGeneric
02/01/2011 - "Assessment of cerebral hemodynamics to acetazolamide using brain perfusion SPECT in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy."
05/15/2010 - "Acetazolamide improves cerebral hemodynamics in CADASIL."
08/01/2000 - "Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking."
06/01/2012 - "Our preliminary experience expands previous reports and confirms the possible efficacy of acetazolamide in CADASIL migraine. "
06/01/2012 - "We retrospectively reviewed our database of patients with a genetic diagnosis of CADASIL to identify how many of them were treated with acetazolamide for the prophylaxis of migraine. "
|4.||KB 2796 (lomerizine)IBA
03/01/2009 - "Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients."
03/01/2009 - "Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine."
01/01/2014 - "Lomerizine hydrochloride might therefore be one option for the treatment of CADASIL. "
01/01/2014 - "We tried lomerizine hydrochloride, which was reported to prevent stroke in a patient with CADASIL. "
01/01/2014 - "[A case of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in which lomerizine hydrochloride was suggested to prevent recurrent stroke]."
|5.||Fibrinolytic Agents (Antithrombotic Agents)IBA
|6.||Adenosine Triphosphate (ATP)IBA
03/01/2014 - "The location of white matter lesions, especially in the anterior temporal poles (ATP), is helpful in the diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). "
03/01/2014 - "We report a 49-year-old man with CADASIL who developed migraine with atypical aura, silent lacunar infarcts, and leukoencephalopathy without involvement of the ATP. "
|7.||atorvastatin (Lipitor)FDA Link
09/15/2007 - "Short term treatment with atorvastatin resulted in no significant improvement of hemodynamic parameters in the overall cohort of CADASIL subjects."
09/15/2007 - "Twenty-four CADASIL subjects were treated with atorvastatin for 8 weeks. "
09/15/2007 - "Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL."
|8.||technetium Tc 99m bicisate (Neurolite)FDA Link
01/01/2011 - "Retinal nerve fiber layer thinning in CADASIL: an optical coherence tomography and MRI study."
08/01/2008 - "The aim of this study is to determine the relationship between retinal abnormalities and brain white matter hyper-intensities (WMH) in symptomatic patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). "
11/01/2013 - "Retinal microvascular changes such as arteriolar narrowing and arteriovenous nicking, described in most patients and detected also in asymptomatic carriers, reflect the typical hemodynamic changes of CADASIL. "
01/01/2011 - "RNFL thinning suggests that retinal axonal loss occurs in CADASIL, even in the absence of subjective visual deficit."
08/01/2008 - "Retinal arteriole narrowing may be associated with the severity of the cerebral lesions in CADASIL."
|10.||Epidermal Growth Factor (EGF)IBA
09/01/2011 - "This report underlines that when CADASIL is suspected the genetic analysis should be performed on all the NOTCH3 exons coding for EGF-like repeats including exon 24 and confirms that CADASIL may have heterogeneous phenotypes."
08/15/2011 - "Our data confirm the importance of screening the whole EGF-like domains region of NOTCH3 gene for the molecular diagnosis of CADASIL among the Italian population too. "
04/15/2008 - "This case report underlines that, when CADASIL is suspected, molecular analysis should be performed on all the NOTCH3 exons coding for EGF-like repeats and not be limited to those where mutations have been found with higher frequency, and that the disease may be encountered also in mildly symptomatic elderly patients. "
01/01/2007 - "CADASIL is caused by mutations in NOTCH3 epidermal growth factor-like repeat that maps to chromosome 19. "
07/15/2006 - "Mutations described here cause an odd number of cysteines in the N-terminal of the EGF domain of Notch3 protein, which seems to have an important functional effect in the pathophysiology of CADASIL. "
|1.||Activities of Daily Living (ADL)
03/01/2014 - "After 21 months of follow-up, deterioration in her cognition and ability to perform instrumental activities of daily living were significant with a follow-up AD8 score of 7. Ascertain Dementia 8 questionnaire is an easy and valid screening tool for early cognitive impairment in patients with CADASIL syndrome."
01/01/2014 - "After adjustment for age, more CADASIL patients were disabled (impaired on ≥ 2 items of the Instrumental Activities of Daily Living scale) in comparison with ARL patients, and CADASIL patients had worse functional performances evaluated with the Disability Assessment for Dementia (DAD) scale. "
01/01/2015 - "Current evidence shows that the efficacy on cognitive function and activities of daily living of cholinesterase inhibitors in people with HD, CADASIL, MS, PSP or FTD is unclear, although cholinesterase inhibitors are associated with more gastrointestinal side effects compared with placebo."
01/01/2015 - "However, the treatment effect on other aspects of cognitive change were unclear, measured by the Selective Reminding Test (3 studies, WMD 1.47, 95% CI -0.39 to 3.32, P = 0.12; high quality evidence), patient's self-reported impression of memory change (2 studies, OR 1.67, 95% CI 0.93 to 3.00, P = 0.08; high quality evidence) and cognitive change (1 study, OR 0.95, 95% CI 0.45 to 1.98, P = 0.89; high quality evidence), clinician's impression of memory change (1 study, OR 1.50, 95% CI 0.59 to 3.84, P = 0.39; moderate quality evidence), other psychometric tests, and activities of daily living - patient reported impact of multiple sclerosis activities (1 study, WMD -1.18, 95% CI -3.02 to 0.66, P = 0.21; low quality evidence).One study on patients with CADASIL found a beneficial effect of cholinesterase inhibitors on the Executive interview, and Trail Making Test parts A and B. "
11/01/2004 - "Scanning laser Doppler flowmetry shows reduced retinal capillary blood flow in CADASIL."
01/01/2014 - "28 eyes of fourteen CADASIL patients and an equal number of control subjects underwent confocal scanning laser ophthalmoscopy (cSLO), spectral-domain optical coherence tomography (SD-OCT), retinal nerve fibre layer (RNFL) measurements, fluorescein and indocyanine angiography. "
06/01/2003 - "Eleven CADASIL patients (7 women, 4 men; mean age, 55.8 +/- 6.7 y) without cortical lesions on brain MR images underwent PET after intravenous injection of 120 MBq (18)F-FDG, with calculation of rCMRglc according to a previously published method. "
08/01/2000 - "We used the MRI bolus tracking method in 15 symptomatic patients with CADASIL (5 with dementia) and 10 age-matched control subjects before and 20 minutes after the intravenous injection of acetazolamide (ACZ, 17 mg/kg). "